Format

Send to

Choose Destination
Adv Exp Med Biol. 2006;586:381-90.

Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers.

Author information

1
Lupus Center of Excellence, University of Pittsburgh School of Medicine, USA.

Abstract

Measurement of serum C3 and C4 has been used for several decades to monitor disease activity in patients with SLE. Despite the limited utility and recognized weaknesses of these assays, they have remained the gold standard during an era of unprecedented discovery in the complement field. The current urgent need for lupus biomarkers warrants efforts to mine the complement system for assays superior to serum C3 and C4. Recent studies of soluble and cell-bound complement activation products hold promise for achieving this goal.

PMID:
16893085
DOI:
10.1007/0-387-34134-X_25
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center